Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
The development of effective methods of obesity treatment with the goal of preventing many associated diseases is among the priorities of modern biomedical research. In 2016 glucagon-like peptide-1 analog (GLP-1) liraglutide 3 mg (Saxenda®) was approved in the Russian Federation for the trea...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2018-04-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://www.omet-endojournals.ru/jour/article/view/9362 |
| _version_ | 1827121755946221568 |
|---|---|
| author | Tatiana I. Romantsova |
| author_facet | Tatiana I. Romantsova |
| author_sort | Tatiana I. Romantsova |
| collection | DOAJ |
| description | The development of effective methods of obesity treatment with the goal of preventing many associated diseases is among the priorities of modern biomedical research. In 2016 glucagon-like peptide-1 analog (GLP-1) liraglutide 3 mg (Saxenda®) was approved in the Russian Federation for the treatment of obesity. This review presents literature data on the effects of GLP-1 and liraglutide on appetite and body weight as well as an analysis of the effectiveness and safety of drug Saxenda based on the results of major clinical trials. |
| first_indexed | 2024-03-08T09:12:59Z |
| format | Article |
| id | doaj.art-2820faebd4394c50812ba15fd3a0ce33 |
| institution | Directory Open Access Journal |
| issn | 2071-8713 2306-5524 |
| language | English |
| last_indexed | 2025-03-20T13:58:11Z |
| publishDate | 2018-04-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Ожирение и метаболизм |
| spelling | doaj.art-2820faebd4394c50812ba15fd3a0ce332024-09-11T16:17:50ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242018-04-0115131110.14341/omet201813-118338Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesityTatiana I. Romantsova0<p>Sechenov First Moscow State Medical University</p>The development of effective methods of obesity treatment with the goal of preventing many associated diseases is among the priorities of modern biomedical research. In 2016 glucagon-like peptide-1 analog (GLP-1) liraglutide 3 mg (Saxenda®) was approved in the Russian Federation for the treatment of obesity. This review presents literature data on the effects of GLP-1 and liraglutide on appetite and body weight as well as an analysis of the effectiveness and safety of drug Saxenda based on the results of major clinical trials.https://www.omet-endojournals.ru/jour/article/view/9362obesityglucagon-like peptide-1appetite regulationliraglutide |
| spellingShingle | Tatiana I. Romantsova Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity Ожирение и метаболизм obesity glucagon-like peptide-1 appetite regulation liraglutide |
| title | Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity |
| title_full | Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity |
| title_fullStr | Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity |
| title_full_unstemmed | Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity |
| title_short | Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity |
| title_sort | gglucagon like peptide 1 analogue liraglutide saxenda r mechanism of action efficacy for the treatment of obesity |
| topic | obesity glucagon-like peptide-1 appetite regulation liraglutide |
| url | https://www.omet-endojournals.ru/jour/article/view/9362 |
| work_keys_str_mv | AT tatianairomantsova gglucagonlikepeptide1analogueliraglutidesaxendamechanismofactionefficacyforthetreatmentofobesity |